Princeton Portfolio Strategies Group LLC lessened its position in Sanofi (NYSE:SNY) by 9.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,677 shares of the company’s stock after selling 2,000 shares during the period. Princeton Portfolio Strategies Group LLC’s holdings in Sanofi were worth $943,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Fisher Asset Management LLC grew its position in shares of Sanofi by 8.1% in the 2nd quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after acquiring an additional 1,022,953 shares during the period. Bank of America Corp DE grew its position in shares of Sanofi by 8.2% in the 1st quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after acquiring an additional 572,652 shares during the period. FMR LLC grew its position in shares of Sanofi by 3.0% in the 2nd quarter. FMR LLC now owns 5,374,385 shares of the company’s stock valued at $257,487,000 after acquiring an additional 155,751 shares during the period. BlackRock Inc. grew its position in shares of Sanofi by 47.6% in the 2nd quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after acquiring an additional 720,523 shares during the period. Finally, Parametric Portfolio Associates LLC grew its position in shares of Sanofi by 1.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,474,261 shares of the company’s stock valued at $70,632,000 after acquiring an additional 13,981 shares during the period. 9.33% of the stock is owned by institutional investors.
A number of research analysts have recently commented on the stock. Cowen and Company reissued a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Argus reissued a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $53.50.
Shares of Sanofi (NYSE SNY) traded down 0.08% during mid-day trading on Friday, hitting $50.57. 1,776,344 shares of the company traded hands. The firm has a 50-day moving average of $49.17 and a 200-day moving average of $47.96. The stock has a market capitalization of $127.01 billion, a price-to-earnings ratio of 11.74 and a beta of 0.87. Sanofi has a one year low of $36.81 and a one year high of $50.65.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, equities analysts predict that Sanofi will post $3.33 earnings per share for the current year.
In related news, major shareholder Sanofi acquired 105,820 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Princeton Portfolio Strategies Group LLC Has $943,000 Stake in Sanofi (SNY)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/10/08/princeton-portfolio-strategies-group-llc-has-943000-stake-in-sanofi-sny.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.